Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liberini V
Authors: Liberini V, Rampado O, Gallio E, De Santi B, Ceci F,
Keywords: radiomic, PRRT, NET, SSTR-RADS, NETPET grade, RECIST 1.1 criteria, 68Ga-DOTATOC PET/CT, tumor/spleen ratio, radiomic analysis of 68Ga-DOTATOC PET/CT, radiomic features,
Introduction: Classification of rectal NEN (rNEN) changed significantly over the years.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Geboes K
Authors: Geboes K, De Maeyer F, De Man M, Ribeiro S, Carton S,
Keywords: rectum, incidence, treatment management, subtypes/who grade,
Introduction: For poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), American Joint Committee on Cancer (AJCC) recommends to use a classification different from that for well-differentiated neuroendocrine tumor. However, this is not adopted by European Neuroendocrine Tumor Society (ENETS) staging classification.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Zhang Y, Chen L, Lin Z, Zhang T, Chen M,
Keywords: gastroenteropancreatic neuroendocrine carcinoma, prognosis, staging,
Introduction: The tumorigenesis of neuroendocrine neoplasm (NEN) are still ambiguous. The therapies of NENs in colon or rectum refer to adenocarcinomas (AC) when tumor metastasis, but the response was unsatisfactory which inspired us to explore the mutation difference.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hu H
Authors: Cai W, Ge W, Wu D, Mao J, Hu H,
Keywords: Neuroendocrine neoplasm, Tumorigenesis, Mutation spectrums, Colorectal,
#2823 Peptide Receptor Radionuclide Therapy in Rectal Neuroendocrine Tumours
Introduction: Neuroendocrine tumours (NETs) arising from the rectum are more common in the Asian population. Current treatment options include somatostatin analogues, chemotherapy, and more recently, peptide-receptor radionuclide therapy (PRRT). Peptide receptor radionuclide therapy (PRRT) has been shown to be effective in the treatment of advanced gastroenteropancreatic (GEP) tumours with minimal adverse effects. Studies have also suggested that rectal NETs show good response to PRRT, better than GEP NETs.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Tham W, Huang H, Tai W, Yan X, Ng C,
Keywords: Neuroendocrine tumours, PRRT,